A cell therapy for blood cancers after stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new cell therapy (BSB-1001) given after a stem cell transplant to prevent or treat high-risk blood cancers like AML, ALL, or MDS. It is for patients with a specific genetic marker and a matched donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 70 years old
- Have a high-risk blood cancer (AML, ALL, or MDS) that has not responded to or has come back after treatment
- Have a specific genetic type (HLA-A*02:01 and HA-1 positive)
- Have a donor who does not have the HA-1 marker and is a 10/10 genetic match
- Weigh no more than 100 kg (about 220 pounds)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests specially engineered donor T cells (TSC-100 or TSC-101) given after a stem cell transplant to help prevent cancer relapse in people with AML, MDS, or ALL. It is for patients who have a specific genetic marker (HA-1 or HA-2) and a matched donor.
This is a Phase 1 trial testing a new drug called BSB-2002 in patients with acute myeloid leukemia (AML) that has come back or stopped responding to previous treatments. The drug is designed specifically for patients whose cancer cells have a particular genetic change (NPM1 mutation) and may help control the cancer by activating the immune system.
This trial tests a new drug combination (SHR2554 and azacitidine) given before a stem cell transplant to treat aggressive leukemias, lymphomas, or bone marrow disorders. The goal is to improve survival and reduce cancer recurrence in patients with high-risk or hard-to-treat disease.
This trial tests whether giving specially engineered donor T-cells after a stem cell transplant can help treat certain blood cancers like AML or MDS. The study is for people receiving a donor stem cell transplant for the first time.
This trial tests a new drug combination (SHR2554 plus azacitidine) given before a stem cell transplant to treat aggressive leukemia, myelodysplastic syndrome, or lymphoblastic leukemia. The goal is to reduce cancer cells before transplant and improve outcomes.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Hear when a new AML, Adult Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.